FDA granted orphan drug designation to the WT1 cancer vaccine developed by SELLAS Life Sciences Group for the treatment of patients with malignant pleural mesothelioma. SELLAS recently reported positive results of a phase II trial of its WT1 vaccine in MPM patients, showing that overall survival improved and progression-free survival doubled. Based on these findings,...
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
